痘苗病毒载体疫苗的进展及其在黄病毒疫苗开发中的应用
本文综述了基于痘苗病毒(VV)的疫苗载体研究进展,包括重组VV的构建方法、VV特异性预存免疫对后续VV载体疫苗的影响及抗原特异性免疫应答,并重点讨论了针对黄病毒的重组VV疫苗,旨在为未来VV疫苗开发提供见解与指导。
要点
- 减毒痘苗病毒(VV)已被验证为有前景的疫苗载体。
- 综述涵盖重组VV构建、预存免疫影响及抗原特异性免疫应答。
- 重点讨论重组VV黄病毒疫苗的进展。
核心结论
- 基于发表数据,本综述旨在为未来基于VV的疫苗开发提供有价值的见解和指导。
研究设计与样本
- 综述,检索范围未在摘要中报告。
主要发现
- 数十年的探索和利用验证了减毒VV作为针对多种致死性病毒的有前景的疫苗载体。
- 综述讨论了重组VV的构建方法、VV特异性预存免疫对后续基于VV的疫苗的影响以及抗原特异性免疫应答。
- 综述集中讨论了基于重组VV的黄病毒疫苗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Historically, virulent variola virus infection caused hundreds of millions of deaths. The smallpox pandemic in human beings has spread for centuries until the advent of the attenuated vaccinia virus (VV) vaccine, which played a crucial role in eradicating the deadly contagious disease. Decades of exploration and utilization have validated the attenuated VV as a promising vaccine vehicle against various lethal viruses. In this review, we focus on the advances in VV-based vaccine vector studies, including construction approaches of recombinant VV, the impact of VV-specific pre-existing immunity on subsequent VV-based vaccines, and antigen-specific immune responses. More specifically, the recombinant VV-based flaviviruses are intensively discussed. Based on the publication data, this review aims to provide valuable insights and guidance for future VV-based vaccine development.
引用
- Xie L, Li Y. Advances in vaccinia virus-based vaccine vectors, with applications in flavivirus vaccine development. Vaccine. 2022. PMID: 36319490. doi:10.1016/j.vaccine.2022.10.047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。